Abstract
Missing Alzheimer's disease (AD) data is prevalent and poses significant challenges for AD diagnosis. Previous studies have explored various data imputation approaches on AD data, but the systematic evaluation of deep learning algorithms for imputing heterogeneous and comprehensive AD data is limited. This study investigates the efficacy of denoising autoencoder-based imputation of missing key features of heterogeneous data that comprised tau-PET, MRI, cognitive and functional assessments, genotype, sociodemographic, and medical history. The authors focused on extreme (≥40%) missing at random of key features which depend on AD progression; identified as the history of a mother having AD, APoE ε4 alleles, and clinical dementia rating. Along with features selected using traditional feature selection methods, latent features extracted from the denoising autoencoder are incorporated for subsequent classification. Using random forest classification with 10-fold cross-validation, robust AD predictive performance of imputed datasets (accuracy: 79%–85%; precision: 71%–85%) across missingness levels, and high recall values with 40% missingness are found. Further, the feature-selected dataset using feature selection methods, including autoencoder, demonstrated higher classification score than that of the original complete dataset. These results highlight the effectiveness and robustness of autoencoder in imputing crucial information for reliable AD prediction in AI-based clinical decision support systems.
| Original language | English |
|---|---|
| Pages (from-to) | 452-460 |
| Number of pages | 9 |
| Journal | Healthcare Technology Letters |
| Volume | 11 |
| Issue number | 6 |
| Early online date | 15 Sept 2024 |
| DOIs | |
| Publication status | Published (in print/issue) - 31 Dec 2024 |
Bibliographical note
© 2024 The Author(s). Healthcare Technology Letters published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.Data Access Statement
The original data that support the findings of this study areavailable from the Alzheimer’s Disease Neuroimaging Initiative(ADNI) dataset, more specifically the ADNIMERGE-3 openrepository at https://adni.loni.usc.edu portal as per request andwas accessed after approval by the Data Sharing and PublicationCommittee of Image and Data Archive (IDA). Processed dataare available upon reasonable request. Codes for the currentstudy are available at https://github.com/NamithaHaridas/Denoising_AE_ADNI/ https://github.com/NamithaHaridas/Denoising_AE_ADNIFunding
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH\u201012\u20102\u20100012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol\u2010Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann\u2010La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
| Funders | Funder number |
|---|---|
| Alzheimer's Association | |
| AbbVie | |
| National Institute on Aging | |
| National Institutes of Health | U01 AG024904 |
| National Institutes of Health | |
| W81XWH‐12‐2‐0012 | |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 5 Gender Equality
-
SDG 9 Industry, Innovation, and Infrastructure
-
SDG 10 Reduced Inequalities
Keywords
- Dementia
- Alzheimer's disease AD
- data imputation
- heterogeneous data
- extreme missing data
- Tau-PET Brain Imaging
- gender
- feature extraction
- machine learning
- deep learning
- denoising autoencoder
- Medical diagnostics
- decision support system
- classification
- medical diagnostic computing
- data mining
- decision support systems
- data reduction
- learning (artificial intelligence)
- feature selection
- neural nets
Fingerprint
Dive into the research topics of 'Autoencoder imputation of missing heterogeneous data for Alzheimer's disease classification'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver